Effect of nanoparticle coating on the immunogenicity of plasmid DNA vaccine encoding P. yoelii MSP-1 C-terminal

Vaccine

Volumn 29, Issue 17, 2011, Pages 3239-3247

  Shuaibu, M N ^a   Cherif, M S ^a   Kurosaki, T ^a   Helegbe, G K ^a   Kikuchi, M ^a   Yanagi, T ^a   Sasaki, H ^a   Hirayama, K ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Cytokines; DNA vaccination; IgG subtypes; Intravenous; Malaria; Nanoparticle

Indexed keywords

CD4 ANTIGEN; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; INTERLEUKIN 12P40; INTERLEUKIN 4; NANOPARTICLE; PLASMID DNA; POLYETHYLENEIMINE; POLYGLUTAMIC ACID; PROTEIN MSP 1; PROTOZOAL PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; COMPLEX FORMATION; CONTROLLED STUDY; DNA IMMUNIZATION; DOSE RESPONSE; DRUG DESIGN; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MATERIAL COATING; MOUSE; NONHUMAN; PLASMODIUM YOELII; PRIORITY JOURNAL; SPLEEN CELL; SUPERNATANT; SURVIVAL; TH2 CELL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DRUG CARRIERS; FEMALE; IMMUNOASSAY; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; MALARIA; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED C57BL; NANOPARTICLES; PLASMODIUM YOELII; SURVIVAL ANALYSIS; TH2 CELLS; VACCINATION; VACCINES, DNA;

EID: 79954578035     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.02.033     Document Type: Article

References (52)

1. Reed Z.H., Friede M., Kieny M.P. Malaria vaccine development: progress and challenges. Curr Mol Med 2006, 6(2):231-245.
2. Richards J.S., Beeson J.G. The future for blood-stage vaccines against malaria. Immunol Cell Biol 2009, 87:377-390.
3. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(4949 Pt 1):1465-1468.
4. Hoffman S.L., Sedegah M., Hedstrom R.C. Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccine. Vaccine 1994, 12:1529-1533.
5. Sedegah M., Hedstrom R., Hobart P., Hoffman S.L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA 1994, 91:9866-9870.
6. O'Hagan D.T., Singh M., Ulmer J.B. Microparticles for the delivery of DNA vaccines. Immunol Rev 2004, 199:191-200.
7. Tyagi R.K., Sharma P.K., Vyas S.P., Mehta A. Various carrier system(s)-mediated genetic vaccination strategies against malaria. Expert Rev Vaccines 2008, 7:499-520.
8. Xiang S.D., Selomulya C., Ho J., Apostolopoulos V., Plebanski M. Delivery of DNA vaccines: an overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2010, 2(3):205-218.
9. Chen S.C., Jones D.H., Fynan E.F., Farrar G.H., Clegg J.C.S., Greenberg H.B., et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol 1998, 72(7):5757-5761.
10. Goh S.L., Murthy N., Xu M., Freche J.M.J. Cross-linked microparticles as carriers for the delivery of plasmid DNA for vaccine development. Bioconjug Chem 2004, 15(3):467-474.
11. Wei K., Fan M., Wu B. The preliminary study of pcDNA3, 1(+)-gbpB-chitosan nanoparticles as a novel nasal delivery system for anti-carious vaccine. Med J Wuhan Univ 2005, 26(3):351-354.
12. McKeever U., Barman S., Hao T., Chambers P., Song S., Lunsford L., et al. Protective immune responses elicited in mice by immunization with formulations of poly (lactide-co-glycolide) microparticles. Vaccine 2002, 20:1524-1531.
13. Mollenkopf H.-J., Dietrich G., Fensterle J., Grode L., Diehl K.-D., Knapp B., et al. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 2004, 22:2690-2695.
14. Wang F., He X.-W., Jiang L., Ren D., He Y., Li D.-A., et al. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice. Vaccine 2006, 24:2017-2026.
15. Wendorf J., Singh M., Chesko J., Kazzaz J., Soewanan E., Ugozzoli M., et al. A practical approach to the use of nanoparticles for vaccine delivery. J Pharm Sci 2006, 95:2738-2750.
16. Combadiere B., Mahe B. Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 2007, 31:293-315.
17. Lutsiak M.E., Kwon G.S., Samuel J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol 2006, 58:739-747.
18. Kurosaki T., Kitahara T., Fumoto S., Nishida K., Nakamura J., Niidome T., et al. Ternary complexes of pDNA, polyethylenimine, and g-polyglutamic acid for gene delivery systems. Biomaterials 2009, 30:2846-2853.
19. Liu S., Danquah M.K., Ho J., Ma C., Wang L., Coppel R., et al. Preparation and characterization of poly (lactic-co-glycolic acid) microparticles containing DNA molecules encoding a malaria vaccine candidate. J Chem Technol Biotechnol 2009, 84:782-788.
20. Singh M., Briones M., Ott G., O'Hagan D. Cationic microparticles: a potent delivery system for DNA vaccines. PNAS 2000, 97(2):811-816.
21. Sedegah M., Rogers W.O., Belmonte A., Belmonte M., Banania G., Patterson N., et al. VaxfectinTM enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 2006, 24:1921-1927.
22. Denis-Mize K.S., Dupuis M., Singh M., Woo C., Ugozzoli M., O'Hagan D.T., et al. Mechanisms of increased immunogenicity for DNA-based vaccines adsorbed onto cationic microparticles. Cell Immunol 2003, 225:12-20.
23. Otten G.R., Schaefer M., Doe B., Liu H., Srivastava I., Megede J.Z., et al. Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. J Virol 2005, 79(13):8189-8200.
24. Helson R., Olszewska W., Singh M., Megede J.Z., Melero J.A., O'Hagan D., et al. Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination. Vaccine 2008, 26:753-761.
25. Luo Y., O'Hagan D., Zhou H., Singh M., Ulmer J., Reisfeld R.A., et al. Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice. Vaccine 2003, 21(17-18):1938-1947.
26. Boyoglu S., Vig M.S., Pillai K., Rangari S., Dennis V., Khazi V.A.F., et al. Enhanced delivery and expression of a nanoencapsulated DNA vaccine vector for respiratory syncytial virus. Nanomedicine 2009, 5(4):463-472.
27. Sakai T., Hisaeda H., Nakano Y., Zhang M., Takashima M., Ishii K., et al. Gene gun-based co-immunization of merozoite surface protein-1 cDNA with IL-12 expression plasmid confers protection against lethal Plasmodium yoelii in A/J mice. Vaccine 2003, 21:1432-1444.
28. Kang Y., Calvo P.A., Daly T.M., Long C.A. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite. J Immunol 1998, 161:4211-4219.
29. Brice G.T., Dobano C., Sedegah M., Stefaniak M., Graber N.L., Campo J.J., et al. Extended immunization intervals enhance the immunogenicity and protective efficacy of plasmid DNA vaccines. Microb Infect 2007, 9:1439-1446.
30. Wang R., Epstein J., Baraceros F.M., Gorak E.J., Charoenvit Y., Carucci D.J., et al. Induction of CD4(+) T cell dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 2001, 98:10817-10822.
31. Epstein J.E., Gorak E.J., Charoenvit Y., Wang R., Freydberg N., Osinowo O., et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 2002, 13:1551-1560.
32. Epstein J.E., Charoenvit Y., Kester K.E., Wang R., Newcomer R., Fitzpatrick S., et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine 2004, 22:1592-1603.
33. Rainczuk A., Scorza T., Spithill T.W., Smooker P.M. A bicistronic DNA vaccine containing apical membrane antigen 1 and merozoite surface protein 4/5 can prime humoral and cellular immune responses and partially protect mice against virulent Plasmodium chabaudi adami DS malaria. Infect Immun 2004, 72(10):5565-5573.
34. Epstein J.E., Gorak E.J., Charoenvit Y., Wang R., Freydberg N., Osinowo O., et al. Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of intramuscular and combination intramuscular/intradermal routes. Hum Gene Ther 2002, 13(13):1551-1560.
35. Belperron A.A., Feltquate D., Fox B.A., Horii T., Bzik D.J. Immune responses induced by gene gun or intramuscular injection of DNA vaccines that express immunogenic regions of the serine repeat antigen from Plasmodium falciparum. Infect Immun 1999, 67(10):5163-5169.
36. Gramzinski R.A., Maris D.C., Obaldia N., Rossan R., Sedegah M., Wang R., et al. Optimization of antibody responses of a malaria DNA vaccine in Aotus monkeys. Vaccine Res 1996, 5(3):173-183.
37. Wang R., Epstein J., Baraceros M.J., Gorak E.J., Charoenvit Y., Carucci D.J., et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. PNAS 2001, 98(19):10817-10822.
38. Kawabata K., Takakura Y., Hashida M. The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharm Res 1995, 12:825.
39. Draper S.J., Goodman A.L., Biswas S., Forbes E.K., Moore A.C., Gilbert S.C., et al. Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host Microbe 2009, 5:95-105.
40. Wipasa J., Xu H., Liu X., Hirunpetcharat C., Stowers A., Good M.F. Effect of Plasmodium yoelii exposure on vaccination with the 19-kilodalton carboxyl terminus of merozoite surface protein 1 and vice versa and implications for the application of a human malaria vaccine. Infect Immun 2008, 77(2):817-824.
41. Jeamwattanalert P., Mahakunkijcharoen Y., Kittigul L., Mahannop P., Pichyangkul S., Hirunpetcharat C. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice. Clin Vaccine Immunol 2007, 14(4):342-347.
42. Ahlborg N., Ling I.T., Holder A.A., Riley E.M. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1-19) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1-19. Infect Immun 2000, 68(4):2102-2109.
43. Pleass R.J., Ogun S.A., McGuinness D.H., van de Winkel J.G.J., Holder A.A., Woof J.M. Novel antimalarial antibodies highlight the importance of the antibody Fc region in mediating protection. Blood 2003, 102:4424-4430.
44. Tongren J.E., Corran P.H., Jarra W., Langhorne J., Riley E.M. Epitope-specific regulation of immunoglobulin class switching in mice immunized with malarial merozoite surface proteins. Infect Immun 2005, 73(12):8119-8129.
45. Ling I.T., Ogun S.A., Momin P., Richards R.L., Garçon N., Cohen J., et al. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine 1997, 15(14):1562-1567.
46. De Souza J.B., Ling I.T., Ogun S.A., Holder A.A., Playfair J.H. Cytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant. Infect Immun 1996, 64(9):3532-3536.
47. Burns J.M., Dunn P.D., Russo D.M. Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood-stage antigens. Infect Immun 1997, 65(8):3138-3145.
48. Spencer Valero L.M., Ogun S.A., Fleck S.L., Ling I.T., Scott-Finnigan T.J., Blackman M.J., et al. Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein 1 suppresses parasitemia. Infect Immun 1998, 66:3925-3930.
49. Su Z., Tam M.F., Jankovic D., Stevenson M.M. Vaccination with novel immunostimulatory adjuvants against blood-stage malaria in mice. Infect Immun 2003, 71(9):5178-5187.
50. Look M., Bandyopadhyay A., Blum J.S., Fahmy T.M. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev 2010, 62:378-393.
51. Constant S.L., Bottomly K. Induction of Th1 and Th2 CD41 Tcell responses: the alternative approaches. Annu Rev Immunol 1997, 15:297-322.
52. Taylor-Robinson A.W., Smith E.C. A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection. Immunol Rev 1999, 171:105-124.